Cochlear (COH) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
18 Jan, 2026Opening remarks and agenda
The meeting was opened by the Chair, acknowledging traditional custodians and welcoming shareholders both in person and online.
Meeting procedures, voting, and Q&A protocols were outlined, with polling open throughout and results to be released to the ASX.
Financial performance review
Achieved record sales revenue of AUD 2.3 billion, up 12% in constant currency, and underlying net profit of AUD 387 million, up 15% in constant currency.
Dividends increased by 24%, with a payout ratio of 69% of underlying net profit.
Net cash exceeded AUD 500 million, supporting investments and capital expenditure.
FY25 guidance targets underlying net profit growth of 6–11%.
Board and executive committee updates
Board renewal continued, with Caroline Clarke appointed and Yasmin Allen retiring.
Female representation on the board rose to 44%.
Directors standing for re-election included Alison Deans, Glen Boreham, and Christine McLoughlin; Caroline Clarke stood for election.
Latest events from Cochlear
- Underlying net profit fell 9% despite stable revenue, with a stronger second half expected.COH
H1 202613 Feb 2026 - Record profit and revenue growth, robust outlook, and continued investment in innovation.COH
H2 20241 Feb 2026 - Sales and profit up, services down; cloud spend and new launches shape cautious outlook.COH
H1 20258 Jan 2026 - Strong implant growth and Nexa launch drive results, offset by services decline and China headwinds.COH
H2 202523 Nov 2025 - Sales, profit, and dividends rose; R&D, board renewal, and global growth remain priorities.COH
AGM 202523 Oct 2025